Stock Financial Ratios, Dividends, Split History

CBRL / Cracker Barrel Old Country Store, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)3,933.71
Enterprise Value ($M)3,862.73
Book Value ($M)640.38
Book Value / Share26.68
Price / Book6.39
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 24,118,288
Common Stock Shares Outstanding 24,055,682
Common Shares Outstanding 24,055,682
Weighted Average Number Of Shares Outstanding Basic 24,031,810
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.21
Return on Assets (ROA)0.13
Return on Equity (ROE)0.38
Balance Sheet (mrq) ($M)
Quick Ratio0.61
Current Ratio1.05
Income Statement (mra) ($M)
Sales Revenue Net2,926,289,000.00
Operating Income313.16
Net Income201.90
Earnings Per Share Basic8.40
Earnings Per Share Diluted8.37
Cash Flow Statement (mra) ($M)
Cash From Operations320.77
Cash from Investing-109.61
Cash from Financing-109.61
Identifiers and Descriptors
Central Index Key (CIK)1067294
Related CUSIPS
22410J956 00022410J 022410J10

Split History

Stock splits are used by Cracker Barrel Old Country Store, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Biglari Holdings Operations Now Valued At Negative $90 Million

2018-07-16 seekingalpha
Recent developments have resulted in the core business being valued materially below zero for first time ever. (3-0)

Buy PayPal Up To $98 - Cramer's Lightning Round (7/10/18)

2018-07-11 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, July 10. (30-0)

Cramer's lightning round: It's time to buy into lithium play Albemarle

2018-07-10 cnbc
Albemarle Corporation: “I think it’s way overdone to the downside. I’d actually pick some up right here, then wait for the next quarter. I think it’s going to be a good one.” (5-0)

Cracker Barrel Strategic Efforts Bode Well: Should You Hold?

2018-07-05 zacks
It has been a volatile year for the Retail-Food & Restaurants industry so far. Year to date, the industry has declined 4% against the S&P 500’s 1.7% gain. Under such circumstances, Cracker Barrel Old Country Store, Inc. (CBRL - Free Report) , which has witnessed its shares rise more than 670% in the last 10 years, is trading sideways in 2018. Even though the company looks promising on its efficient cost-saving initiatives, higher labor costs and expenses related to various sales-boosting initiatives are weighing on its margins. (1-0)

Cracker Barrel (CBRL) Up 4% Since Earnings Report: Can It Continue?

2018-06-21 zacks
It has been about a month since the last earnings report for Cracker Barrel Old Country Store, Inc. (CBRL - Free Report) . Shares have added about 4% in that time frame. (26-0)

CUSIP: 22410J106